- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Apr 7, 2016
Highlights
- Market Cap
- $34.72B
- Enterprise Value
- $34.62B
- EPS (TTM)
- -$0.88
- Total Revenue (TTM)
- $90.49M
- EBITDA (TTM)
- -$171.29M
- Year Range
- $14.00 - $101.71
- Target Price
- $81.90
- ROA (TTM)
- -23.49%
- ROE (TTM)
- -26.75%
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
SYRE Performance Chart
Spyre Therapeutics Inc. (SYRE) is up 206.2% since the beginning of the year. At $100 per share, SYRE is trading just below its 52-week high of $102. Investors who bought $1,000 worth of SYRE shares 5 years ago would now be looking at an investment worth $614.
Loading charts...
Returns By Period
Spyre Therapeutics Inc. (SYRE) has returned 206.23% so far this year and 568.35% over the past 12 months. Over the last ten years, SYRE has returned -2.85% per year, falling short of the S&P 500 Index benchmark, which averaged 13.88% annually.
Spyre Therapeutics Inc.
- 1D
- 13.56%
- 1M
- 35.48%
- YTD
- 206.23%
- 6M
- 193.33%
- 1Y
- 568.35%
- 3Y*
- 115.67%
- 5Y*
- -9.28%
- 10Y*
- -2.85%
Benchmark (S&P 500 Index)
- 1D
- -0.37%
- 1M
- -0.01%
- YTD
- 9.16%
- 6M
- 8.64%
- 1Y
- 25.22%
- 3Y*
- 19.78%
- 5Y*
- 11.99%
- 10Y*
- 13.88%
SYRE Monthly Returns History
Based on dividend-adjusted daily data since Apr 7, 2016, SYRE's average daily return is +0.19%, while the average monthly return is +3.07%. At this rate, an investment would double in approximately 1.9 years.
Historically, 46% of months were positive and 54% were negative. The best month was Jun 2023 with a return of +246.8%, while the worst month was Jun 2022 at -68.0%. The longest winning streak lasted 5 consecutive months, and the longest losing streak was 7 months.
On a daily basis, SYRE closed higher 48% of trading days. The best single day was Jun 22, 2023 with a return of +328.7%, while the worst single day was Nov 30, 2022 at -66.0%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -2.38% | 34.49% | 17.28% | 47.60% | -1.28% | 36.49% | 206.23% | ||||||
| 2025 | -1.25% | -14.31% | -18.10% | -5.61% | 0.33% | -2.03% | 13.36% | -2.83% | 1.64% | 45.94% | 22.65% | 9.20% | 40.72% |
| 2024 | 20.40% | 5.91% | 38.23% | -12.92% | 5.81% | -32.73% | 16.97% | 4.55% | 2.30% | 10.61% | -12.60% | -18.11% | 8.18% |
| 2023 | 11.14% | -21.60% | -26.02% | -41.83% | -23.00% | 246.81% | 25.44% | 1.75% | -14.78% | -4.98% | 60.31% | 15.33% | 91.33% |
| 2022 | -9.47% | -35.58% | -16.97% | -37.39% | 9.72% | -68.03% | -17.76% | 25.90% | 0.57% | 95.82% | -59.71% | 8.41% | -90.53% |
| 2021 | -11.69% | 7.19% | 6.31% | -1.77% | -15.04% | 5.30% | -11.93% | 18.27% | 9.66% | -7.92% | -14.75% | -23.88% | -39.64% |
Benchmark Metrics
Spyre Therapeutics Inc. has an annualized alpha of 36.81%, beta of 1.24, and R2 of 0.03 versus S&P 500 Index. Calculated based on daily prices since April 07, 2016.
- This stock participated in 146.10% of S&P 500 Index downside but only 53.63% of its upside - more exposed to losses than it benefited from rallies.
- R2 of 0.03 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 36.81%
- Beta
- 1.24
- R²
- 0.03
- Upside Capture
- 53.63%
- Downside Capture
- 146.10%
Return for Risk
Risk / Return Rank
SYRE ranks 99 for risk / return — in the top 99% of stocks on our site. This means strong returns relative to risk — exactly what professional investors look for. Well-suited for investors who want to maximize return per unit of risk.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for Spyre Therapeutics Inc. (SYRE) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| SYRE | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +6.32 | ||
| Sortino ratioReturn per unit of downside risk | +3.53 | ||
| Omega ratioGain probability vs. loss probability | 1.74 | 1.37 | +0.37 |
| Calmar ratioReturn relative to maximum drawdown | 34.16 | 2.78 | +31.37 |
| Martin ratioReturn relative to average drawdown | 95.79 | 12.44 | +83.35 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Spyre Therapeutics Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Spyre Therapeutics Inc. was 99.11%, occurring on Jun 21, 2023. The portfolio has not yet recovered.
The current Spyre Therapeutics Inc. drawdown is 66.53%.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
2023 bear market2023 | -99.11%Jun 2023 | 7y 2mo | — | 10y 2moApr 2016 - now |
2016 pullback2016 | -2.30%Apr 2016 | 0s | 1d | 1dApr 2016 - Apr 2016 |
Drawdown Indicators
| SYRE | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -99.11% | -56.78% | -42.33% |
Max Drawdown (1Y)Largest decline over 1 year | -16.79% | -9.10% | -7.69% |
Max Drawdown (3Y)Largest decline over 3 years | -73.99% | -18.90% | -55.09% |
Max Drawdown (5Y)Largest decline over 5 years | -98.74% | -25.43% | -73.31% |
Max Drawdown (10Y)Largest decline over 10 years | -99.04% | -33.92% | -65.12% |
Current DrawdownCurrent decline from peak | -66.53% | -1.80% | -64.73% |
Average DrawdownAverage peak-to-trough decline | -62.69% | -10.71% | -51.98% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 5.98% | 2.03% | +3.95% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Spyre Therapeutics Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Spyre Therapeutics Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for SYRE relative to other companies in the Biotechnology industry. Currently, SYRE has a P/S ratio of 225.4. This P/S ratio is high relative to other companies in the industry. It could mean the stock is overvalued, or that investors expect strong future growth and profitability.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for SYRE in comparison with other companies in the Biotechnology industry. Currently, SYRE has a P/B value of 66.2. This P/B ratio is higher than most companies in the industry. It may suggest the stock is overvalued or that investors expect the company to generate high returns on its assets.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with SYRE
Add Spyre Therapeutics Inc. to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with SYRE